Table 3. Randomized studies on (neo-)adjuvant chemotherapy and resection of hepatic metastases of colorectal carcinoma.
| Author | Year | Number of patients | Regimen | Disease-free survival | Overall survival |
| Lygidakis (e56) | 2001 | 62 / 60 | resection + immunotherapy + 5-FU vs. resection + HAI immunotherapy + 5-FU | – | 5 years: (p = 0.05) |
| 73% vs. 60% | |||||
| Lorenz (21) | 1998 | 113 / 113 | resection vs. | median: 14.2 vs. 13.7 | median: 34.5 vs. 40.8 |
| resection + HAI 5-FU / LV | months (n.s.) | months (n.s.) | |||
| Kemeny (20) | 2005 | 74 / 82 | resection + 5-FU vs. | median: 17 vs. 31 | 10 years: (n.s.) |
| resection + HAI FUDR + 5-FU | months (p<0.05) | 27.2% vs. 41.1% | |||
| Portier (22) | 2006 | 86 / 85 | resection vs. | 5 years: (p = 0.028) | 5 years: (p = 0.13) |
| resection + 5-FU / LV | 50% vs. 33% | 51% vs. 42% | |||
| Mitri (23) | 2008 | 140 / 138 | resection vs. | median: 18.8 vs. 27.9 | median: 47.3 vs. 62.2 |
| resection + 5-FU / LV | months (p = 0.058) | months (p = 0.095) | |||
| Nordlinger (25) | 2008 | 182 / 182 | resection vs. resection + perioperative FOLFOX | 3 years: (p = 0.058) | NA |
| 28.1% vs. 35.4% |
5-FU, 5-fluorouracil; LV, leucovorin; HAI, intra-arterial infusion in the hepatic artery; FUDR, floxuridine; NA, data not available; n.s., not significant; FOLFOX, folic acid, 5-FU, and oxaliplatin